Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase 2b Study of Betalutin in Third Line Advanced Follicular Lymphoma Patients who are Refractory to Anti-CD20 Therapy

Next Previous
Trial Profile

A Pivotal Phase 2b Study of Betalutin in Third Line Advanced Follicular Lymphoma Patients who are Refractory to Anti-CD20 Therapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-177 lilotomab satetraxetan (Primary)
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGME
  • Sponsors Nordic Nanovector

    • Most Recent Events

    • 15 Sep 2022 According to a Nordic Nanovector media release, this study was discontinued due to slow recruitment and subsequent disappointing data from the trial.
    • 05 Jul 2022 According to a Nordic Nanovector media release, the company will host a webcast on 6 July, 2022 elaborating on the strategic decision to stop this study.
    • 05 Jul 2022 According to a Nordic Nanovector media release, the the Board is of the opinion that the demonstrated profile is no longer sufficiently competitive to bring Betalutin to the market in the third line relapsed and refractory FL indication, within a timeframe that makes financial and commercial sense for the Company.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top